HE 2100

Drug Profile

HE 2100

Alternative Names: HE2100; NEUMUNE

Latest Information Update: 24 May 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Virginia Commonwealth University
  • Developer Armed Forces Radiobiology Research Institute
  • Class Androstenediols; Radioprotectives; Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Neutropenia; Nosocomial infections; Radiation injuries

Most Recent Events

  • 20 Mar 2007 HE 2100 is available for licensing (http://www.holliseden.com)
  • 17 Mar 2007 Discontinued - Phase-I for Radiation injuries in Netherlands (Injection)
  • 17 Mar 2007 Discontinued - Phase-I for Radiation injuries in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top